GGrantIndex
Sort

40,608 grants matching prostate cancer

Intermittent Fasting using a Fasting-Mimetic Diet to Improve Prostate Cancer Control and Metabolic Outcomes

$722,345
Stephen Jay Freedland · Cedars-Sinai Medical Center · R01 · FY2023 · CA

Recovery Support for Bladder CA Patients and Caregivers: A Multimodal Approach

$722,281
Michael A Diefenbach · Feinstein Institute For Medical Research · R01 · FY2018 · CA

Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer

$722,240
Goutam Chakraborty · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA

Carolina Community Network

$722,192
Paul A. Godley · Univ Of North Carolina Chapel Hill · U01 · FY2009 · CA

Improving Quality of Life of Prostate Cancer Survivors with Androgen Deficiency

$721,908
Shalendar Bhasin · Brigham And Women'S Hospital · R01 · FY2022 · AG

GCDH Addiction in Melanoma

$721,672
Ze'ev A Ronai · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2023 · CA

Selenium and Vitamin E Chemoprevention Trial (SELECT

$721,474
La Biomed Res Inst/ Harbor Ucla Med Ctr · M01 · FY2004 · RR

HEREDITARY X-LINKED TUMOR SUPPRESSOR ESCAPES IMMUNE CONTROL IN PROSTATE CANCER

$721,426
Health Research, Inc. · · FY2019 · Defense Health Agency

Computational Methods for Identifying Non-coding Cancer Drivers

$721,394
Ekta Khurana · Weill Medical Coll Of Cornell Univ · R01 · FY2020 · CA

Early Detection Research Network (EDRN) BiomarkerReferenceResourceCenter (BRRC)

$721,387
National Cancer Institute · Y01 · FY2010 · CA

Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer

$720,928
Jose M. Garcia · Seattle Inst For Biomedical/Clinical Res · R01 · FY2019 · CA

Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas Southwestern

$720,852
Martin G Sanda · Emory University · U01 · FY2023 · CA

Tumor Growth and Microenvironment Influence T Cell Tolerance to Tumor Antigens

$720,716
Arthur Hurwitz · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

Restore: Improving Sexual Outcomes of Gay and Bisexual Prostate Cancer Survivors

$720,659
B. R. Simon Rosser · University Of Minnesota · R01 · FY2018 · CA

TARGETING KINASES IN PROSTATE CANCER

$720,630
The Trustees Of Columbia University In The City Of New York · · FY2011 · Department of the Army

Role of Novel Cytokine-like Molecule Secretoglobin (SCGB) 3A2 in Lung

$720,526
Shioko Kimura · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Optimizing Treatment of Prostate Cancer in Men living with HIV

$720,465
Keith Magnus Sigel · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA

Theranostic DLL3/PSMA-bi-specific CAR-T cells for prostate cancer therapy

$720,416
Vladimir Ponomarev · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA

Characterizing genetic risk of cancer across diverse populations through multi-ancestry epigenome profiling and chromatin QTL discovery

$720,252
Sylvan C. Baca · Dana-Farber Cancer Inst · U01 · FY2025 · CA

FREQUENT LOSS OF CHD1 IN THE PROSTATE CANCER OF AFRICAN AMERICANS AND ITS POTENTIAL ROLE IN INCREASED SENSITIVITY TO PLATINUM OR PARP INHIBITOR-BASED

$720,195
Children'S Hospital Corporation, The · · FY2018 · Defense Health Agency

Augmenting PSMA expression to enhance PSMA directed therapeutic efficacy

$720,165
Michael C Haffner · Fred Hutchinson Cancer Center · R37 · FY2024 · CA

PEPTIDE BEAD MICROARRAYS MEASURED BY MASS SPECTROMETRY IMAGING

$720,069
Vladislav Bergo · Adeptrix Corporation · R44 · FY2016 · GM

IDENTIFICATION OF EPIGENETIC CHANGES IN PROSTATE CANCER USING INDUCED PLURIPOTENT STEM CELLS

$720,034
The Leland Stanford Junior University · · FY2010 · Department of the Army

Translational Pathology Core Facility

$719,937
Sue Ellen Martin · University Of Southern California · P30 · FY2008 · CA

PSMA’s enzymatic activity as new target for Prostate Cancer diagnosis and therapy

$719,857
Jan Grimm · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA